Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.
作者信息
Khan Md Saiful Islam, Khan Md Sakirul Islam, Debnath Chitto Ranjan, Nath Progga Nanda, Mahtab Mamun Al, Nabeka Hiroaki, Matsuda Seiji, Akbar Sheikh Mohammad Fazle
机构信息
COVID-19 Management Team, Mymensingh Medical College and Hospital, Mymensingh, Bangladesh.
Department of Anatomy and Embryology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
出版信息
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
Abstract
摘要
相似文献
1
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠病毒肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbr.2020.08.011. Epub 2020 Dec 14.
2
Considerations on the Article "Antiviral and Anti-Inflammatory Properties of Ivermectin and its Potential Use in COVID-19".关于《伊维菌素的抗病毒和抗炎特性及其在COVID-19中的潜在用途》一文的思考
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):832. doi: 10.1016/j.arbres.2020.08.012. Epub 2020 Sep 16.
3
Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.伊维菌素治疗可能改善新冠肺炎患者的预后。
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):828-830. doi: 10.1016/j.arbres.2020.08.007. Epub 2020 Sep 24.
4
Unethical studies of ivermectin for covid-19.关于伊维菌素用于治疗新冠病毒的不道德研究。
BMJ. 2022 Apr 14;377:o917. doi: 10.1136/bmj.o917.
5
A five-day course of ivermectin may reduce the duration of COVID-19 illness.为期五天的伊维菌素疗程可能会缩短新冠病毒疾病的病程。
Int J Infect Dis. 2021 Sep;110:93-94. doi: 10.1016/j.ijid.2021.07.050. Epub 2021 Jul 26.
6
Letter in reply: more power to ivermectin multidrug therapy.回信：伊维菌素多药疗法更具效力。
Future Microbiol. 2022 Nov;17:1283-1285. doi: 10.2217/fmb-2022-0184. Epub 2022 Sep 22.
7
Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina.在阿根廷图库曼的医护人员中，使用伊维菌素和iota-卡拉胶进行强化治疗作为COVID-19暴露前预防措施。
Am J Ther. 2021 Aug 16;28(5):e601-e604. doi: 10.1097/MJT.0000000000001433.
8
Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19.伊维菌素的抗病毒和抗炎特性及其在COVID-19中的潜在用途
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):831. doi: 10.1016/j.arbres.2020.06.011. Epub 2020 Jul 7.
9
Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?基于宿主的治疗药物用于治疗2019冠状病毒病（COVID-19）：抗病毒机制与抗癌机制之间的联系？
Int J Antimicrob Agents. 2020 Sep;56(3):106125. doi: 10.1016/j.ijantimicag.2020.106125. Epub 2020 Jul 30.
10
Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible?伊维菌素对新冠病毒的抗病毒作用——从临床角度看是否合理？
Int J Infect Dis. 2021 Aug;109:91. doi: 10.1016/j.ijid.2021.06.048. Epub 2021 Jun 24.
引用本文的文献
1
Association between ivermectin treatment and mortality in COVID-19: A hospital-based case-control study.伊维菌素治疗与 COVID-19 死亡率之间的关联：一项基于医院的病例对照研究。
J Family Med Prim Care. 2023 Jan;12(1):139-144. doi: 10.4103/jfmpc.jfmpc_1163_22. Epub 2023 Feb 15.
2
Outcome of Ivermectin in Cancer Treatment: An Experience in Loja-Ecuador.伊维菌素在癌症治疗中的效果：厄瓜多尔洛哈的一项经验
Nurs Rep. 2023 Feb 22;13(1):315-326. doi: 10.3390/nursrep13010030.
3
Results of a systematic review and meta-analysis of early studies on ivermectin in SARS-CoV-2 infection.系统评价和荟萃分析早期伊维菌素治疗 SARS-CoV-2 感染的研究结果。
Geroscience. 2023 Aug;45(4):2179-2193. doi: 10.1007/s11357-023-00756-y. Epub 2023 Mar 7.
4
Prospective mode of action of Ivermectin: SARS-CoV-2.伊维菌素的前瞻性作用模式：严重急性呼吸综合征冠状病毒2
Eur J Med Chem Rep. 2022 Apr;4:100018. doi: 10.1016/j.ejmcr.2021.100018. Epub 2021 Nov 22.
5
Efficacy of Therapeutic Plasma Exchange in Severe Acute Respiratory Distress Syndrome in COVID-19 Patients from the Western Part of Romania.罗马尼亚西部地区 COVID-19 患者严重急性呼吸窘迫综合征中治疗性血浆置换的疗效。
Medicina (Kaunas). 2022 Nov 23;58(12):1707. doi: 10.3390/medicina58121707.
6
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years.用于预防和治疗新型冠状病毒肺炎及其并发症的药物：过去两年我们所了解情况的最新进展
Front Pharmacol. 2022 Oct 10;13:987816. doi: 10.3389/fphar.2022.987816. eCollection 2022.
7
Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial.伊维菌素治疗轻度至中度 COVID-19 感染的疗效和安全性：一项随机、双盲、安慰剂对照试验。
Trials. 2022 Aug 26;23(1):714. doi: 10.1186/s13063-022-06649-3.
8
Microbiome-Based Hypothesis on Ivermectin's Mechanism in COVID-19: Ivermectin Feeds Bifidobacteria to Boost Immunity.基于微生物群的伊维菌素在COVID-19中作用机制的假说：伊维菌素通过滋养双歧杆菌来增强免疫力。
Front Microbiol. 2022 Jul 11;13:952321. doi: 10.3389/fmicb.2022.952321. eCollection 2022.
9
Is Ivermectin Effective in Treating COVID-19?伊维菌素对治疗新冠肺炎有效吗？
Front Pharmacol. 2022 Jun 21;13:858693. doi: 10.3389/fphar.2022.858693. eCollection 2022.
10
Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases.COVID-19 感染对既往呼吸道疾病的短期和长期影响。
Arch Bronconeumol. 2022 Apr;58 Suppl 1:39-50. doi: 10.1016/j.arbres.2022.03.011. Epub 2022 Apr 15.
本文引用的文献
1
Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain.西班牙一家大学医院中60岁及以上新冠病毒疾病患者的合并症与死亡率
Arch Bronconeumol (Engl Ed). 2020 Nov;56(11):756-758. doi: 10.1016/j.arbres.2020.06.012. Epub 2020 Jul 16.
2
Antiviral and Anti-Inflammatory Properties of Ivermectin and Its Potential Use in COVID-19.伊维菌素的抗病毒和抗炎特性及其在COVID-19中的潜在用途
Arch Bronconeumol (Engl Ed). 2020 Dec;56(12):831. doi: 10.1016/j.arbres.2020.06.011. Epub 2020 Jul 7.
3
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019（COVID-19）的病理生理学、传播、诊断和治疗：综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
4
Clinical Characteristics and Factors Associated With Long-Term Viral Excretion in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Single-Center 28-Day Study.严重急性呼吸综合征冠状病毒 2 感染患者长期病毒排出的临床特征及相关因素：一项单中心 28 天研究。
J Infect Dis. 2020 Aug 17;222(6):910-918. doi: 10.1093/infdis/jiaa388.
5
The role of peripheral blood eosinophil counts in COVID-19 patients.外周血嗜酸性粒细胞计数在 COVID-19 患者中的作用。
Allergy. 2021 Feb;76(2):471-482. doi: 10.1111/all.14465. Epub 2020 Jul 13.
6
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.伊维菌素：从抗病毒作用到 COVID-19 补充治疗方案的系统评价。
J Antibiot (Tokyo). 2020 Sep;73(9):593-602. doi: 10.1038/s41429-020-0336-z. Epub 2020 Jun 12.
7
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.干扰素 beta-1b、洛匹那韦利托那韦和利巴韦林三联治疗住院 COVID-19 患者：一项开放标签、随机、2 期试验。
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
8
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.针对 SARS-CoV-2 的免疫反应和 COVID-19 中免疫病理变化的机制。
Allergy. 2020 Jul;75(7):1564-1581. doi: 10.1111/all.14364.
9
SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression.痰液中的新冠病毒载量与新冠病情进展风险相关。
Crit Care. 2020 Apr 23;24(1):170. doi: 10.1186/s13054-020-02893-8.
Zotero 插件